# A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Source: https://onco.cc/trials/nct06868199/  
OnCo record `nct06868199` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Toripalimab in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.

## Summary

A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06868199 by LaNova Medicines Limited, with 87 participants planned, started 2025-05-06 and due to reach its primary completion in 2027-08-01. Interventions recorded: LM-168 and Toripalimab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06868199
- Phase: 1/2
- Setting: A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
- Sponsor: LaNova Medicines Limited
- Enrolled: 87

## Sources

- ClinicalTrials.gov NCT06868199: https://clinicaltrials.gov/study/NCT06868199

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [LaNova Medicines](https://onco.cc/companies/lanova-medicines/)

---
JSON: https://onco.cc/api/v1/entities/nct06868199.json